Tag: pharma

The company\’s revenue from operations increased by 18% to Rs 2,552.4 crore as against Rs 2,163.6 crore in the corresponding period of the preceding fiscal.

As the Q4 FY24 earnings season is going on, Goldman Sachs (NYSE:GS) analysts have recalibrated their projections for the Indian pharmaceutical sector, factoring in a spectrum of variables from monthly sales data to currency fluctuations. Notably, the sector continues to trade at valuations exceeding one standard deviation above its five-year average, largely propelled by the resilience of major players like Sun Pharma (NS:SUN), Cipla (NS:CIPL), and Divi’s Laboratories.

Markets anticipate election impact. May series will be volatile, says Rahul Ghose of Hedged.in. He says a stock-specific approach is advisable now and that he prefers Hindustan Unilever, Elecon and Just Dial and recommends exiting Exide. Nifty\’s crucial levels are at 21,700-21,800, 22,000. PSU banks are favored while Nifty Pharma index is pivotal at 18,700. IPCA labs strong.

Kenneth Andrade anticipates significant growth in the power market, emphasizing massive investments in energy capex equivalent to India\’s GDP over the next 15 years. He discusses the impact on various sectors and the rationale behind his pharma holdings, focusing on profitability potential. Andrade says he is avoiding banks because he chooses to be on the asset side and not on the liability side.

6 companies expected to double sales in Q4 with sectors like automobiles, banks, gas utilities, pharmaceuticals showing YoY sales growth. Sunteck Realty set for a significant jump in net sales.

29 companies expected to double profits in Q4FY24 across various sectors like BFSI, Auto, Healthcare. Notable companies include Adani Ports, KEC International, Birla Corporation, JK Cements, United Breweries, Gland Pharma, Quess Corp Ltd, Signature Global, NMDC.

​​T​hey also purchased insurance stocks like SBI Life, HDFC Life, and ICICI Prudential Life Insurance after favourable guidelines on the surrender value of policies were announced by the insurance regulator IRDAI. Also, the recent removal of the age limit on availing of health insurance is seen as boosting the prospects of life insurance companies.

Rajesh Cheruvu\’s insights point to a positive market momentum in FY25 driven by central bank rate cuts, primary industries capex, and potential earnings recovery, particularly in small & midcaps. Cheruvu says sustained domestic participation in equities coinciding with the formalization of businesses post-pandemic has helped attract interest in mid & small-sized firms. Investors should be considering sectoral allocation and gold hedging strategies for the year.

Sensex and Nifty plummeted as FPIs sold off, influenced by US inflation and tweak in India-Mauritius tax treaty. Investors are also cautious on valuations, profit booking, and rising commodities prices. EPS growth is likely to moderate in Q4 earnings season which begins today with TCS.

Foram Parekh shares insights on CDMO companies\’ positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus\’s earnings improvement, Sun Pharma\’s specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy\’s.

Global broking firm Goldman Sachs on Friday initiated coverage on Syngene International and Neuland Labs with buy ratings but gave a sell call on Laurus Labs.